Market News

Galmed Dips 2% On Larger-Than-Expected Quarterly Loss

Galmed Pharmaceuticals declined 2% to close at $3.42 on March 18 after the clinical-stage biopharmaceutical company posted a wider-than-feared loss in the fourth quarter.

Galmed (GLMD) incurred a loss of $0.48 per share in 4Q, compared to the $0.36 loss per share estimated by analysts. The company reported a loss of $0.39 per share in the prior-year quarter.

Research and development expenses grew 21.6% year-over-year to $9 million driven by clinical trial costs. General and administrative expenses remained flat at $1.3 million. (See Galmed stock analysis on TipRanks)

Earlier this week, Galmed announced the treatment of the first subject in the First-in-Human Phase I clinical trial evaluating Amilo-5MER, designed for the treatment of chronic inflammatory diseases.

Following the 4Q results, Raymond James analyst Steven Seedhouse decreased the stock’s price target to $14 (309.4% upside potential) from $17 and maintained a Buy rating.

According to Seedhouse, “Most incremental in today’s update is that Galmed initiated their Phase 1a study evaluating Amilo-5mer in IBD with topline data expected in 2H21.”

The consensus rating among analysts is a Strong Buy based on 4 unanimous Buys. The average analyst price target stands at $17.25 and implies upside potential of 404% to current levels over the next 12 months.

Related News:
Signet Jewelers’ Sales Outlook Tops Estimates After 4Q Beat; Shares Jump Pre-Market
Smartsheet Posts Better-Than-Feared Quarterly Loss, Sales Outperform
Jabil’s Sales Guidance Tops Estimates After 2Q Beat; Shares Jump Pre-Market

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More